Литература. 
Сучасні аспекти застосування статинів при гострому коронарному синдромі

1. Сусенков А. В. Ингибиторы ГМГ-КоA-редуктазы при вторичной профилактике атеросклероза: 30 лет спустя // Consilium medicum. — 2005. — № 11. — С. 896−903.2. Aikawa M., Rabkin E., Sugiyama S. et al. An HMG-CoA reductase inhibitors, cerivastatin, suppresses grown of macrophages expressing matrix metalloproteinases and tissue factor in vitro and in vivo // Circulation. — 2001. — Vol. 103. — P. 276−283.3. Aikawa M., Sugiyama S., Hill C.C. et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma // Circulation. — 2002. — Vol. 106. — P. 1390−1396.4. Arntz H.R., Agrawal R., Wunderlich W. et al. Beneficial effects of pravastatin (± cholestyramine/niacin) initiated immediately after a coronary event. The randomised lipid coronary artery disease (L-CAD) study // Am. J. Cardiol. — 2000. — Vol. 86. — P. 1293−1298.5. A to Z Trial Investigators. Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial // JAMA. — 2004. — Vol. 292. — P. 1307−1316.6. Bavry A.A., Mood G.R., Kumbhani D.J. et al. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials // Am. J. Cardiovasc Drugs. — 2007. — Vol. 7. — P. 135−141.7. Behague I., Poirier O., Nicaud V. et al. Fibrinogen gene polymorphysms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM Study // Circulation. — 1996. — Vol. 93. — P. 440−449.8. Blanco-Colio L.M., Villa A., Ortego M. Et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation // Atherosclerosis. — 2002. — Vol. 161. — P. 17−26.9. Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells // Arterioscler Thromb. Vasc Biol. — 2000. — Vol. 20. — P. 556−562.10. Cannon C.P., Braunvald E., McCabe C.H. et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy — Trombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes // New Engl. J. Med. — 2004. — Vol. 350. — P. 1495−1504.11. Cortellaro M., Cofrancesco E., Arbustini E. et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study // Thromb Haemost. — 2002. — Vol. 88. — P. 41−47.12. Crisby M., Nordin-Fredriksson G., Shah P.K. et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization // Circulation. — 2001. — Vol. 103. — P. 926−933.13. Davidson M., McKenney J., Stein E. et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hyperholesterolemia // Am. J. Cardiol. — 1997. — Vol. 79. — P 1475−1481.14. de Divitiis M., Rubba P., Di Somma S. et al. Effect of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia // Am. J. Cardiol. — 1996. — Vol. 78. — P. 763−768.15. den Hartog F.R., Verheugt F.W.A. Early HMG-CoA reductase inhibition in acute coronary syndromes: preliminary data of therapeutic pravastatin in acute ischaemic syndromes study (PAIS) // Eur. Heart J. — 1998. — Vol. 19 (Suppl.). — Abstract 492.16. Diomede L., Albani D., Sottocorno M. et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products // Arterioscler. Thromb. Vasc. Biol. — 2001. — Vol. 21. — P. 1327−1332.17. Duрuis J., Tardif J., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of therapeutic Endothelium) Trial // Circulation. — 1999. — Vol. 99. — P. 3227−3233.18. Eto M., Luscher T.F. Modulation of coagulation and fibrinolytic pathways by statins // Endothelium. — 2003. — Vol. 10. — P. 35−41.19. Ferro D., Basili S., Alessandri C. et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin // Atherosclerosis. — 2000. — Vol. 149. — P. 111−116.20. Fonarow G.C., Gawlinski A., Moughrabi S. et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) // Amer. J. Cardiol. — 2001. — Vol. 87. — P. 819−822.21. Gottsater A., Anwaar I., Lind P. et al. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin // Blood Coagul. Fibrinolysis. — 1999. — Vol. 10. — P. 133−140.22. Green F., Humphries S. Control of plasma fibrinogen levels // Baillieres Clin. Haematol. — 1989. — Vol. 2. — P. 945−959.23. Guidelines for the diagnosis and treatment non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology // Eur. Heart J. — 2007. — Vol. 28. — P. 1598−1660.24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial // Lancet. — 2002. — Vol. 360. — P. 7−22. 25. Heeschen C., Hamm C.W., Laufs U. et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes // Circulation. — 2002. — Vol. 105. — P. 1446−1452.26. Holm T., Andreassen A.K., Ueland T. et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients // Am. J. Cardiol. — 2001. — Vol. 87. — P. 815−818.27. Jialal I., Stein D., Balis D. et al. Effect of hydroxymethyl glutaryl Coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels // Circulation. — 2001. — Vol. 103. — P. 1933;1935.28. Joukhadar C., Klein N., Prinz M. et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia // Thromb. Haemost. — 2001. — Vol. 85. — P. 47−51.29. Kayikcioglu M., Turkoglu C., Kultursay H. et al. Combined use of pravastatin and thrombolytic agents in acute myocardial infarction. Pravastatin Turkish trial // Circulation. — 1999. — Vol. 100 (Suppl. I). — P. 1−303.30. Kinlay S., Ganz P. Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy // Am. J. Cardiol. — 2000. — Vol. 86. — Suppl. 8B. — P. 10J-13J. 31. Kinlay S., Schwartz G.G., Olsson A.G. et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL Study // Circulation. — 2003. — Vol. 108. — P. 1560−1566.32. Kitamoto S., Nakano K., Hirouchi Y. et al. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates // Arterioscler Thromb. Vasc. Biol. — 2004. — Vol. 24. — P. 1522−1528.33. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors // Circulation. — 1998. — Vol. 97. — P. 1129−1135.34. Lefer D.J., Scalia R., Jones S.P. et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia reperfusion injury // FASEB J. — 2001. — Vol. 15. — P. 1454−1456.35. Libby P., Aikawa M., Kinlay S. et al. Lipid lowering improves endothelial function // Int. J. Cardiology. — 2000. — Vol. 74 (Suppl. 1). — P. 3−10.36. Libby P., Aikawa M. Mechanisms of plaque stabilization with statins // Am. J. Cardiol. — 2003. — Vol. 91. — P. 4B-8B.37. Libby P., Theroux P. Pathophysiology of coronary artery disease // Circulation. — 2005. — Vol. 111. — P. 3481−3488.38. Libby P., Sasiela W. Plaque stabilization: Can we turn theory into evidence? // Am. J. Cardiol. — 2006. — Vol. 98. — P. S26-S33. 39. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis // J. Intern. Med. — 2008. — Vol. 263. — P. 517−527. 40. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention on cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // New Engl. J. Med. — 1998. — Vol. 339. — P. 1349−1357.41. Miller I., Besta F., Schulz C. et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel // Circulation. — 2003. — Vol. 108. — P. 2195−2197.42. Musial J., Undas A., Undas R. et al. Treatment with simvastatin and low dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline high cholesterol levels // Thromb. Haemost. — 2001. — Vol. 85. — P. 221−225.43. Ni W., Egashira K., Kataoka C. et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis // Circulat. Res. — 2001. — Vol. 89. — P. 415−421.44. O’Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month // Circulation. — 1997. — Vol. 95. — P. 1126−1131.45. Okazaki S., Yokoyama T., Miyauchi K. et al. Early Statin Treatment in Patients With Aacute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study // Circulation. — 2004. — Vol. 110. — P. 1061−1068.46. Ortego M., Bustos C., Hernandes-Preza M.A. et al. Atorvastatin reduces NF-kB activation and hemokine expression in vascular smooth muscle cells and mononuclear cells // Atherosclerosis. — 1999. — Vol. 147. — P. 253−261.47. Plenge J.K., Hernandes T.L., Weil K.M. Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction //Circulation. — 2002. — Vol. 106. — P. 1447−1452.48. Pourati I., Kimmelstiel C., Rand W., Karas R.H. Statin use is associated with enhanced collateralization of severely diseased coronary arteries // Am. Heart J. — 2003. — Vol. 146. — P. 876−881.49. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy // New Engl. J. Med. — 1998. — Vol. 339. — P. 436−443.50. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. — 1994. — Vol. 344. — P. 1383−1389.51. Riesen W.F., Engler H., Risch M. et al. Short-term effects of atorvastatin on C-reactive protein // Eur. Heart J. — 2002. — Vol. 23. — P. 794−799.52. Ridker P.M., Rifai N., Pfeffer M.A. et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators // Circulation. — 1999. — Vol. 100. — P. 230−235.53. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia // Circulation. — 2001. — Vol. 103. — P. 1191−1193.54. Ridker P.M., Cannon C.P., Morrow D. et al. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. — 2005. — Vol. 352. — P. 20−28.55. Ridker P.M., Morrow D.A., Rose L.M. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l: an analysis of the PROVE-IT TIMI-22 trial // Am. Coll. Cardiol. — 2005. — Vol. 45. — P. 1644−1648.56. Rubba P. Effects of atorvastatin on the different phases of atherogenesis // Drugs. — 2007. — Vol. 67. — Suppl 1. — P. 17−27.57. Salbach P., Lang S., Kuchler D. et al. Short-term treatment with atorvastatin: decrease of inflammatory markers and binding activity of NF-kappa B in patients with hyperholesterolemia // Eur. Heart J. — 2001. — Vol. 22. — P. 644.58. Satoh K., Ichihara K. Lipophilic HMGCoA reductase inhibitors increase myocardial stunning in dogs // J. Cardiovasc. Pharmacol. — 2000. — Vol. 35. — P. 256−262.59. Schwartz G.G., Ollson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // JAMA. — 2001. — Vol. 285. — P. 1711−1718.60. Seljeflot I., Tonstad S., Hjermann I., Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease // Thromb. Res. — 2002. — Vol. 105. — P. 285−290. 61. Shepherd J., Cobbe S.M., Ford I. et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hyperholesterolemia // New Engl. J. Med. — 1995. — Vol. 333. — 1301−1307. 62. Sparrow C.P., Burton C.A., Hernandez M. et al. Simvastatin has anti-inflammatory and antiatherosclerotic activites independent of plasma cholesterol lowering // Arterioscler. Thromb. Vasc. Biol. — 2001. — Vol. 21. — P. 115−121.63. Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival // JAMA. — 2001. — Vol. 285. — P. 430−437.64. Treasure C.B., Klein J.L., Weintraub W.S. et al. Beneficial effect of cholesterol-lovering therapy on the coronary endothelium in patients with coronary artery disease // New Engl. J. Med. — 1995. — Vol. 332. — P. 481−487.65. Undas A., Brummel K.E., Musial J. et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation // Circulation. — 2001. — Vol. 103. — P. 2248−2253.66. Walter D.H., Rittig K., Bahlmann F.H. et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells // Circulation. — 2002. — Vol. 105. — P. 3017−3024.67. van Boven A.J., Jukema J.W., Zwinderman A.H. et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris // Circulation. — 1996. — Vol. 94. — P. 1503−1505.68. Vasa M., Fichtlscherer S., Adler K. et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease // Circulation. — 2001. — Vol. 103. — P. 2885−2890.69. Wassmann S., Laufs U., Muller K. et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo // Arterioscler. Thromb. Vasc. Biol. — 2002. — Vol. 22. — P. 300−305.70. Waters D.D., Ku I. Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation // J. Am. Coll. Cardiol. — 2009. — Vol. 54. — P. 1434−1437.71. Wolfrum S., Grimm M., Heidbreder M. et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme a reductase inhibitor is mediated by endothelial nitric oxide synthase // J. Cardiovasc. Pharmacol. — 2003. — Vol. 41. — P. 474−480.72. Wolfrum S., Jensen K.S., Liao J.K. Endothelium-Dependent Effects of Statins // Arterioscler Thromb Vasc Biol. — 2003. — Vol. 23. — P. 729−736.73. Zhu Q., McMaster J., Mymin D. Et al. Effects of atorvastatin treatment on the oxidatively modified low-density lipoprotein in hyperlipidemic patients // Mol. Cell. Biochem. — 2000. — Vol. 207. — P. 9−17.